Thryve Peptides
GLP-1S (10mg)
GLP-1S (10mg)
Couldn't load pickup availability
GLP-1S 10MG
Precision peptide research — focused on incretin pathway mechanisms.
- GLP-1S is a long-acting synthetic peptide analog of GLP-1 (glucagon-like peptide-1), designed for research investigating metabolic regulation and glucose signaling.
- Explored in laboratory studies for its influence on insulin secretion, energy balance, and appetite signaling pathways.
- Independently tested and verified by Vanguard Laboratory for purity and identity.
For laboratory research use only. Not for human consumption.
Scientific Evidence
Semaglutide is a modified GLP-1 receptor agonist with enhanced half-life and receptor affinity. Research has focused on its dual impact on glucose-dependent insulin release and gastric emptying rate modulation.
Studies demonstrate that Semaglutide mimics endogenous GLP-1 actions through activation of cyclic AMP pathways in pancreatic β-cells (PubMed 27685622).
Investigations in metabolic and obesity models (SUSTAIN trials) confirm its potential relevance in long-term glycemic control research (PubMed 28931113).
Regulatory Status: Semaglutide is not FDA-approved for use outside regulated or clinical settings. This product is intended exclusively for research purposes.
